Researchers at the National Institutes of Health (NIH) and Oregon Health & Science University (OHSU) have found that an experimental vaccine elicits antibodies that can protect nonhuman primates from Ebola virus infection. Ebola virus causes severe hemorrhagic fever in humans and nonhuman primates, meaning that infection may lead to shock, bleeding and multi-organ failure. According to the World Health Organization, Ebola hemorrhagic fever has a fatality rate of up to 90 percent. There is no licensed treatment or vaccine for Ebola virus infection.
Several research groups have developed experimental vaccine approaches that protect nonhuman primates from Ebola virus and the closely related Marburg virus. These approaches include vaccines based on DNA, recombinant adenovirus, virus-like particles, and human parainfluenza virus 3. But how these vaccine candidates confer protection is an area that is still being explored: Do they activate immune cells to kill the invading virus? Or do they elicit antibodies that block infection?
In this study, scientists at NIH's National Institute of Allergy and Infectious Diseases and OHSU's Vaccine & Gene Therapy Institute built on earlier work with an experimental vaccine composed of an attenuated vesicular stomatitis virus carrying a gene that codes for an Ebola virus protein. They observed how cynomolgus macaques responded to a challenge of Ebola virus before and during treatment with the vaccine and in conjunction with depleted levels of immune cells. Their results showed that important immune cells—CD4+ T cells and CD8+ T cells—had a minimal role in providing protection, while antibodies induced by the vaccine appeared to be critical to protecting the animals.
The scientists say this finding will help improve future Ebola virus vaccine development. They plan to focus their studies on what level of antibody production is needed to establish protection from Ebola virus infection in humans
WHO: Heinz Feldmann, M.D., Ph.D., chief of the Laboratory of Virology at NIAID's Rocky Mountain Laboratories. Dr. Feldmann is an expert on viral hemorrhagic fevers and emerging viruses.
ARTICLE: A Marzi et al. Antibodies are necessary for rVSV/ZEBOV-GP mediated protection against lethal Ebola virus challenge in nonhuman primates. Proceedings of the National Academy of Sciences. DOI: 10.1073/pnas.1209591110 (2013).
NIH/National Institute of Allergy and Infectious Diseases: http://www.niaid.nih.gov
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
Megafauna like elephants and rhinos are ecological engineers, creating conditions that hundreds of other species have evolved to exploit. Losing their last remaining populations will radically alter life on Earth
Previously stable glaciers have been melting rapidly since 2009
With over 19,000 carcasses buried and more deaths expected officials are no closer to determining the cause of the catastrophe.
How do you check how many of the critically endangered fairy possums are still around? Talk to them, of course
A bloom of bioluminescent plankton has wowed crowds along a river in Southern Tasmania this week, but it could be a warning sign of climate change
During commencement speech at U.S. Coast Guard Academy, president says we must act now to reduce emissions - or else
A company official said the line was operating at full capacity when it broke, suggesting much more oil escaped than initially estimated
A new report predicts that widespread growth in wind power will put many migratory and endangered birds at risk
"This momentous decision marks the beginning of the end for dolphin hunting in Japan"
The bear is the original inspiration for the "Teddy Bear"